問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of Hematology & Oncology

Division of Others-

Division of General Internal Medicine

National Taiwan University Hospital Hsin-Chu Branch (在職)

Division of Hematology & Oncology

更新時間：2023-09-19

陳建源Chen, Chien-Yuan
  • Principal Investigator
  • Clinical Trial Experience (year) 17 years 9 個月

Recruiting Trial

16Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

陳建源

List

48Cases

2017-05-24 - 2022-09-30

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2016-01-01 - 2017-12-31

Phase III

Completed
A PHASE 3 OPEN-LABEL RANDOMIZED STUDY OF QUIZARTINIB (AC220) MONOTHERAPY VERSUS SALVAGE CHEMOTHERAPY IN SUBJECTS WITH FLT3-ITD POSITIVE ACUTE MYELOID LEUKEMIA (AML) REFRACTORY TO OR RELAPSED AFTER FIRST-LINE TREATMENT WITH OR WITHOUT HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) CONSOLIDATION

  • Condition/Disease

    Acute Myeloid Leukemia (AML)

  • Test Drug

    Quizartinib (AC220)

Participate Sites
5Sites

Terminated4Sites

2017-12-01 - 2025-12-31

Phase III

A Phase 3 randomized, open-label, multicenter study assessing the clinical benefit of isatuximab (SAR650984) in combination with bortezomib (Velcade®), lenalidomide (Revlimid®) and dexamethasone versus bortezomib, lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not eligible for transplant

  • Condition/Disease

    Newly Diagnosed Multiple Myeloma (NDMM)

  • Test Drug

    Isatuximab

Participate Sites
5Sites

Recruiting4Sites

2017-04-01 - 2021-12-31

Phase III

A phase 3 randomized, open-label, multicenter study comparing isatuximab in combination with pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with refractory or relapsed and refractory multiple

  • Condition/Disease

    multiple myeloma

  • Test Drug

    Isatuximab

Participate Sites
5Sites

Terminated4Sites

2010-09-30 - 2012-08-31

Phase IV

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2012-11-01 - 2017-03-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2017-11-15 - 2021-03-31

Phase III

A Randomized, Multicenter, Open-label, Phase 3 Study to Compare Daratumumab, Bortezomib, and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Chinese Subjects With Relapsed or Refractory Multiple Myeloma

  • Condition/Disease

    Relapsed or Refractory Multiple Myeloma

  • Test Drug

    Daratumumab

Participate Sites
2Sites

Terminated2Sites

2017-07-01 - 2023-01-31

Phase III

A Phase 3, Multicenter, Randomized, Controlled, Open-label Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)

  • Condition/Disease

    Multiple Myeloma

  • Test Drug

    Daratumumab

Participate Sites
3Sites

Terminated3Sites

2016-12-01 - 2019-12-31

Phase III

A Phase 3, Multicenter, Randomized, Double Blind, Study of Bortezomib and Dexamethasone in Combination with Either Venetoclax or Placebo in Subjects with Relapsed or Refractory Multiple Myeloma Who are Sensitive or Naïve to Proteasome Inhibitors

  • Condition/Disease

    Relapsed or Refractory Multiple Myeloma

  • Test Drug

    Venetoclax (ABT-199)

Participate Sites
6Sites

Terminated5Sites

蕭樑材
Taipei Veterans General Hospital

Division of Hematology & Oncology

2017-08-01 - 2023-05-31

Phase III

A Randomized, Double-Blind, Placebo Controlled Phase 3 Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Subjects With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy

  • Condition/Disease

    Acute Myeloid Leukemia (AML)

  • Test Drug

    Venetoclax (ABT-199/GDC-0199)

Participate Sites
5Sites

Terminated4Sites

1 2 3 4 5
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB